These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

212 related articles for article (PubMed ID: 19968068)

  • 1. [Comparison of modified Bethesda assay and Nijmegen assay in detecting FVII inhibitor in patients with hemophilia A].
    Fan LK; Wang ZW; Hua BL; Su W; Wang SJ; Zhao YQ
    Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2009 Oct; 31(5):551-4. PubMed ID: 19968068
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Validation of 4% albumin as a diluent in the Bethesda Assay for FVIII inhibitors.
    Kershaw GW; Chen LS; Jayakodi D; Dunkley SM
    Thromb Res; 2013; 132(6):735-41. PubMed ID: 24119613
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Modified Bethesda, modified Nijmegen and blank assays for coagulation factor VIII inhibitor detection and factors affecting the results].
    Feng HM; Li Q; Xu WS; Chen DM; Zheng L
    Nan Fang Yi Ke Da Xue Xue Bao; 2016 Apr; 36(4):592-5. PubMed ID: 27113194
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nijmegen-Bethesda assay to measure factor VIII inhibitors.
    Duncan E; Collecutt M; Street A
    Methods Mol Biol; 2013; 992():321-33. PubMed ID: 23546724
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparative measurement of anti-factor VIII antibody by Bethesda assay and ELISA reveals restricted isotype profile and epitope specificity.
    Towfighi F; Gharagozlou S; Sharifian RA; Kazemnejad A; Esmailzadeh K; Managhchi MR; Shokri F
    Acta Haematol; 2005; 114(2):84-90. PubMed ID: 16103630
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Diagnostic and prognostic value of factor VIII binding antibodies in acquired hemophilia A: data from the GTH-AH 01/2010 study.
    Werwitzke S; Geisen U; Nowak-Göttl U; Eichler H; Stephan B; Scholz U; Holstein K; Klamroth R; Knöbl P; Huth-Kühne A; Bomke B; Tiede A
    J Thromb Haemost; 2016 May; 14(5):940-7. PubMed ID: 26988717
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A flow cytometry evaluation of anti-FVIII antibodies: correlation with ELISA and Bethesda assay.
    Irigoyen MB; Primiani L; Felippo M; Candela M; Bianco RP; De Bracco MM; Galassi N
    Haemophilia; 2011 Mar; 17(2):267-74. PubMed ID: 21070488
    [TBL] [Abstract][Full Text] [Related]  

  • 8. ELISA system for detection of immune responses to FVIII: a study of 246 samples and correlation with the Bethesda assay.
    Sahud MA; Pratt KP; Zhukov O; Qu K; Thompson AR
    Haemophilia; 2007 May; 13(3):317-22. PubMed ID: 17498082
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Improvements in factor VIII inhibitor detection: From Bethesda to Nijmegen.
    Verbruggen B; van Heerde WL; Laros-van Gorkom BA
    Semin Thromb Hemost; 2009 Nov; 35(8):752-9. PubMed ID: 20169511
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Thrombin generation as objective parameter of treatment response in patients with severe haemophilia A and high-titre inhibitors.
    Luna-Záizar H; Beltrán-Miranda CP; Esparza-Flores MA; Soto-Padilla J; Bergés-García A; Rodríguez-Zepeda MD; Pompa-Garza MT; Jaloma-Cruz AR
    Haemophilia; 2014 Jan; 20(1):e7-14. PubMed ID: 24354488
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Development of a new modified Bethesda method for coagulation inhibitors: the Osaka modified Bethesda method.
    Torita S; Suehisa E; Kawasaki T; Toku M; Takeo E; Tomiyama Y; Nishida S; Hidaka Y
    Blood Coagul Fibrinolysis; 2011 Apr; 22(3):185-9. PubMed ID: 21245748
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of clot-based, chromogenic and fluorescence assays for measurement of factor VIII inhibitors in the US Hemophilia Inhibitor Research Study.
    Miller CH; Rice AS; Boylan B; Shapiro AD; Lentz SR; Wicklund BM; Kelly FM; Soucie JM;
    J Thromb Haemost; 2013 Jul; 11(7):1300-9. PubMed ID: 23601690
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antibodies to factor VIII in plasma of patients with hemophilia A and normal subjects.
    Batlle J; Gómez E; Rendal E; Torea J; Lourés E; Couselo M; Vila P; Sedano C; Tusell X; Magallón M; Quintana M; González-Boullosa R; López-Fernández MF
    Ann Hematol; 1996 May; 72(5):321-6. PubMed ID: 8645745
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparative measurement of FVIII inhibitors in hemophilia A patients using ELISA and the Bethesda assay.
    Kim SY; Kang SY; Lee WI
    Korean J Lab Med; 2010 Jun; 30(3):260-3. PubMed ID: 20603586
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The between-laboratory variation of factor VIII inhibitor testing: the experience of the external quality assessment program of the ECAT foundation.
    Meijer P; Verbruggen B
    Semin Thromb Hemost; 2009 Nov; 35(8):786-93. PubMed ID: 20169515
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Laboratory assessment of factor VIII inhibitor titer: the North American Specialized Coagulation Laboratory Association experience.
    Peerschke EI; Castellone DD; Ledford-Kraemer M; Van Cott EM; Meijer P;
    Am J Clin Pathol; 2009 Apr; 131(4):552-8. PubMed ID: 19289591
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Does the presence of von Willebrand factor in FVIII-deficient plasma influences the measurement of FVIII inhibitor titres in haemophilia A patients?
    Pouplard C; Desconclois C; Sobas F; Aillaud MF; Ternisien C; Caron C
    Int J Lab Hematol; 2015 Feb; 37(1):125-32. PubMed ID: 24815078
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Limit of detection and threshold for positivity of the Centers for Disease Control and Prevention assay for factor VIII inhibitors.
    Miller CH; Boylan B; Shapiro AD; Lentz SR; Wicklund BM;
    J Thromb Haemost; 2017 Oct; 15(10):1971-1976. PubMed ID: 28795528
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Frequency of factor VIII inhibitor in the patients with hemophilia A and environmental risk factors for inhibitor development].
    Yan ZY; Fan LK; Li KX; Wang XY; Hua BL; Wang SJ; Zhao YQ
    Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2009 Oct; 31(5):580-3. PubMed ID: 19968075
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A detailed comparison of the performance of the standard versus the Nijmegen modification of the Bethesda assay in detecting factor VIII:C inhibitors in the haemophilia A population of Canada. Association of Hemophilia Centre Directors of Canada. Factor VIII/IX Subcommittee of Scientific and Standardization Committee of International Society on Thrombosis and Haemostasis.
    Giles AR; Verbruggen B; Rivard GE; Teitel J; Walker I
    Thromb Haemost; 1998 Apr; 79(4):872-5. PubMed ID: 9569207
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.